Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...

If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.